HER2 / ErbB2 Rabbit polyclonal Antibody IgG
Fig1: Western blot analysis of ErbB2 on different cell lysates using anti- ErbB2 antibody at 1/500 dilution.
Lane 1: SKOV-3
Lane 2: SKBR-3
Fig2: ICC staining ErbB2 in SKOV-3 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Fig3: Immunohistochemical analysis of paraffin-embedded human stomach carcinoma tissue using anti-Her 2 antibody. Counter stained with hematoxylin.
Host Species; Species ReactivityRabbit; Human
Application SummaryWB, ICC, IHC
Purification; FormulationPeptide affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesReceptor tyrosine-protein kinase erbB-2,Metastatic lymph node gene 19 protein,Proto-oncogene Neu,Proto-oncogene c-ErbB-2,Tyrosine kinase-type cell surface receptor HER2,p185erbB2,CD_antigen: CD340
BackgroundHER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Amplification or overexpression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. In recent years the protein has become an important biomarker and target of therapy for approx. 30% of breast cancer patients. Over-expression is also known to occur in ovarian, stomach, and aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma. The expression of HER2 is regulated by signaling through estrogen receptors. Normally, estradiol and tamoxifen acting through the estrogen receptor down-regulate the expression of HER2. However, when the ratio of the coactivator AIB-3 exceeds that of the corepressor PAX2, the expression of HER2 is upregulated in the presence of tamoxifen, leading to tamoxifen-resistant breast cancer.(ER0106)